Palisade Bio (PALI) Return on Sales (2011 - 2023)
Palisade Bio (PALI) reported Return on Sales of 0.52% for Q4 2023, up 5.03% on a QoQ basis from 0.55% in Q3 2023.
Palisade Bio (PALI) has 12 years of Return on Sales data on file, last reported at 0.52% in Q4 2023.
- Quarterly Return on Sales changed N/A year-over-year to 0.52% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.52% (changed N/A YoY) and the FY2023 annual result came in at 0.52%, changed N/A from the prior year.
- Return on Sales grew to 0.52% in Q4 2023 per PALI's latest filing, from 0.55% in the prior quarter.
- Across five years, Return on Sales topped out at 0.1% in Q1 2023 and bottomed at 63.66% in Q3 2022.
- The 4-year median for Return on Sales is 7.37% (2020), against an average of 14.31%.
- The widest annual swing landed in 2020, when Return on Sales tumbled 524 bps; it then surged 6311 bps in 2023.
- Tracing PALI's Return on Sales over 4 years: stood at 8.5% in 2019, then sank by 62 bps to 13.74% in 2020, then slumped by 363 bps to 63.66% in 2022, then soared by 99 bps to 0.52% in 2023.
- Per Business Quant, the three latest PALI Return on Sales figures stand at 0.52% (Q4 2023), 0.55% (Q3 2023), and 0.58% (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.00% |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.52% |
| Sep 30, 2023 | -0.55% |
| Jun 30, 2023 | -0.58% |
| Mar 31, 2023 | -0.10% |
| Sep 30, 2022 | -63.66% |
| Jun 30, 2022 | -29.08% |
| Mar 31, 2022 | -59.30% |
| Dec 31, 2020 | -13.74% |
| Sep 30, 2020 | -7.35% |
| Jun 30, 2020 | -7.37% |
| Mar 31, 2020 | -3.29% |
| Dec 31, 2019 | -8.50% |
| Sep 30, 2019 | -8.44% |
| Jun 30, 2019 | -2.42% |
| Mar 31, 2019 | -9.72% |
| Dec 31, 2018 | -7.14% |
| Sep 30, 2018 | -8.27% |
| Jun 30, 2018 | -0.08% |
| Mar 31, 2018 | -9.33% |
| Dec 31, 2017 | -0.09% |
| Sep 30, 2017 | -10.28% |
| Jun 30, 2017 | -16.88% |
| Mar 31, 2017 | -17.40% |
| Dec 31, 2016 | -6.66% |
| Sep 30, 2016 | -20.56% |
| Jun 30, 2016 | -16.57% |
| Mar 31, 2016 | -26.44% |
| Dec 31, 2015 | -19.10% |
| Sep 30, 2015 | -22.55% |
| Jun 30, 2015 | -21.75% |
| Mar 31, 2015 | -17.32% |
| Dec 31, 2014 | -10.84% |
| Sep 30, 2014 | -8.91% |
| Jun 30, 2014 | -7.78% |
| Mar 31, 2014 | -13.40% |
| Dec 31, 2013 | -12.79% |
| Sep 30, 2013 | -16.26% |
| Jun 30, 2013 | -14.63% |
| Mar 31, 2013 | -0.29% |
| Dec 31, 2012 | -10.86% |
| Sep 30, 2012 | -0.15% |
| Jun 30, 2012 | -0.30% |
| Mar 31, 2012 | -0.16% |
| Dec 31, 2011 | -0.09% |
| Sep 30, 2011 | -0.31% |